UY24893A1 - Combinaciones para diabetes de sulfonilurea glitazona - Google Patents

Combinaciones para diabetes de sulfonilurea glitazona

Info

Publication number
UY24893A1
UY24893A1 UY24893A UY24893A UY24893A1 UY 24893 A1 UY24893 A1 UY 24893A1 UY 24893 A UY24893 A UY 24893A UY 24893 A UY24893 A UY 24893A UY 24893 A1 UY24893 A1 UY 24893A1
Authority
UY
Uruguay
Prior art keywords
sulfonylurea
glitazone
antidiabetic agent
diabetes
combinations
Prior art date
Application number
UY24893A
Other languages
English (en)
Spanish (es)
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY24893A1 publication Critical patent/UY24893A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY24893A 1997-02-19 1998-02-17 Combinaciones para diabetes de sulfonilurea glitazona UY24893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19

Publications (1)

Publication Number Publication Date
UY24893A1 true UY24893A1 (es) 1998-07-10

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24893A UY24893A1 (es) 1997-02-19 1998-02-17 Combinaciones para diabetes de sulfonilurea glitazona

Country Status (29)

Country Link
US (2) US5859037A (enExample)
EP (1) EP0957923A1 (enExample)
JP (1) JP2001512478A (enExample)
KR (1) KR20000071179A (enExample)
CN (1) CN1244801A (enExample)
AR (1) AR011829A1 (enExample)
AU (1) AU741215B2 (enExample)
BG (1) BG103671A (enExample)
BR (1) BR9714505A (enExample)
CA (1) CA2272478A1 (enExample)
CZ (1) CZ289299A3 (enExample)
EA (1) EA199900725A1 (enExample)
EE (1) EE9900345A (enExample)
GT (1) GT199800037A (enExample)
HN (1) HN1997000167A (enExample)
HU (1) HUP0001528A3 (enExample)
IL (1) IL130027A (enExample)
IS (1) IS5058A (enExample)
NO (1) NO993982L (enExample)
NZ (1) NZ336002A (enExample)
PA (1) PA8447401A1 (enExample)
PE (1) PE74399A1 (enExample)
PL (1) PL335166A1 (enExample)
SK (1) SK111899A3 (enExample)
SV (1) SV1998000010A (enExample)
TR (1) TR199902033T2 (enExample)
UY (1) UY24893A1 (enExample)
WO (1) WO1998036755A1 (enExample)
ZA (1) ZA981343B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
DE122007000054I1 (de) * 1997-06-18 2007-12-13 Smithkline Beecham Plc Behandlung der Diabetes mit Thiazolidindione und metformin
PL198018B1 (pl) * 1997-06-18 2008-05-30 Smithkline Beecham Plc Kompozycja farmaceutyczna przeciwcukrzycowa zawierająca sulfonylomocznik i tiazolidynodion i jej zastosowanie
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DK1143955T3 (da) * 1998-12-24 2005-11-14 Metabasis Therapeutics Inc En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
CA2367955C (en) * 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
EP1145717B1 (en) 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20050053677A (ko) 2002-09-20 2005-06-08 안드렉스 랩스 엘엘씨 비구아나이드와 티아졸리디네디온 유도체를 함유한 약제학적 투여형태
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
SI2868315T1 (sl) 2007-12-04 2017-10-30 Biogen Chesapeake Llc Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CN108191846B (zh) * 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
BR112012029858B1 (pt) * 2010-05-24 2021-01-19 Ozstar Therapeutics Pty Ltd. uso de inulina para fabricação de um medicamento
CN108392263A (zh) 2011-01-19 2018-08-14 弗拉克泰尔实验室公司 用于组织处理的装置与方法
KR102104384B1 (ko) * 2011-11-23 2020-04-27 오즈스타 테라피우틱스 피티와이 엘티디 개선된 상승작용성 항-당뇨병성 조성물
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
CA2865567C (en) 2012-02-27 2022-10-11 Fractyl Laboratories, Inc. Heat ablation systems, devices and methods for the treatment of tissue
CA2869904C (en) 2012-04-19 2020-04-21 Fractyl Laboratories, Inc. Systems for expanding tissue prior to energy ablation
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
EP2903626A4 (en) 2012-10-05 2016-10-19 Fractyl Lab Inc METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
JP6603660B2 (ja) 2013-11-22 2019-11-06 フラクティル ラボラトリーズ インコーポレイテッド 消化管における治療制約の生成のためのシステム、デバイスおよび方法
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
WO2016011269A1 (en) 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
CN114853868A (zh) 2014-10-24 2022-08-05 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12403138B2 (en) * 2019-11-22 2025-09-02 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021146535A1 (en) 2020-01-15 2021-07-22 Fractyl Laboratories, Inc. Automated tissue treatment devices, systems, and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
ZA981343B (en) 1998-11-16
BR9714505A (pt) 2000-03-21
CZ289299A3 (cs) 1999-11-17
KR20000071179A (ko) 2000-11-25
PE74399A1 (es) 1999-08-20
BG103671A (en) 2000-04-28
IL130027A (en) 2005-09-25
CN1244801A (zh) 2000-02-16
AR011829A1 (es) 2000-09-13
JP2001512478A (ja) 2001-08-21
NZ336002A (en) 2002-03-28
NO993982D0 (no) 1999-08-18
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
IS5058A (is) 1999-05-27
US5972973A (en) 1999-10-26
WO1998036755A1 (en) 1998-08-27
EP0957923A1 (en) 1999-11-24
PA8447401A1 (es) 2001-12-14
EA199900725A1 (ru) 2000-04-24
NO993982L (no) 1999-08-18
TR199902033T2 (xx) 2000-02-21
AU741215B2 (en) 2001-11-29
SV1998000010A (es) 1999-02-02
SK111899A3 (en) 2000-09-12
CA2272478A1 (en) 1998-08-27
AU5590898A (en) 1998-09-09
PL335166A1 (en) 2000-04-10
HN1997000167A (es) 1999-02-09
EE9900345A (et) 2000-02-15
HUP0001528A3 (en) 2000-12-28
IL130027A0 (en) 2000-02-29
US5859037A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
UY24893A1 (es) Combinaciones para diabetes de sulfonilurea glitazona
BR9810172A (pt) Tratamento de diabete com tiazolidinadiona e metformina
AR020973A1 (es) Combinacion para diabetes
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
BR9911656A (pt) Composição farmacêutica, processos para prevenção ou tratamento de diabetes em um mamìfero, para prevenção ou tratamento de complicações diabéticas em um mamìfero e para prevenção ou tratamento da tolerância a glicose prejudicada em um mamìfero, uso de um sensibilizador de insulina, e, proceso para reduzir os efeitos colaterais de um sensibilizador de insulina ou/ e um anorético administrado a um mamìfero diabético
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
ATE228849T1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
BG105431A (en) METHOD FOR TREATING DIABETES EMPLOYING AN Ap2 INHIBITOR AND COMBINATION
PT1173197E (pt) Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido
BR9810445A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e diguanida
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
BR9810444A (pt) Tratamento de diabete com rosiglitazona e insulina
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
BR9810142A (pt) Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
PT785787E (pt) Utilizacao de derivados de 1,5-benzodiazepina para o controlo de esvaziamento gastrico em doentes com diabetes mellitus nao-insulino dependentes
BR8906377A (pt) Agente para a fixacao do penteado e para o tratamento dos cabelos
HK1041201A1 (zh) 貝塔激動劑和抗糖尿病製劑的配伍
ES2135353A1 (es) Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.
CO5150158A1 (es) Tratamiento antidiabetico novedoso
ECSP982417A (es) Combinaciones para diabetes de sulfonilurea glitazona

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041105